{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:56:11Z","timestamp":1776318971943,"version":"3.50.1"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T00:00:00Z","timestamp":1608508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100008130","name":"Helsinn Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Chemotherapy-induced nausea and vomiting (CINV) contributes to avoidable acute care, a metric now tracked in Medicare's oncology outcome measure. CINV is preventable, yet guidelines are often not followed. We sought to quantify acute care involving CINV and other avoidable toxicities after highly emetogenic chemotherapy (HEC) to identify excess risk and assess clinician adherence to antiemesis guidelines for HEC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>We retrospectively evaluated U.S. electronic health records (2012-2018) using Medicare's OP-35 outcome measure to identify avoidable acute care involving any of 10 toxicities, including CINV, after HEC regimens relative to non-HEC. Antiemetic guideline adherence was defined as use ofneurokinin-1 (NKl) receptor antagonists Q5 (RAs) plus 5-hydroxytryptamine type 3 RA+ dexamethasone at HEC initiation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 17,609 patients receiving HEC, acute care rates associated with HEC chemotherapy included 32% cisplatin, 31% carboplatin, and 21% anthracycline\/cyclosphospharnide (AC), with 76% meeting the criteria as avoidable events. Oxaliplatin rates were 29%. Avoidable acute care occurred 1.83 times (95% confidence interval, 1.76-1.91, p &amp;lt; .0001) as often after HEC versus non-HEC excluding oxaliplatin; CINV-related acute care occurred 2.29 times as often. Nonadherence to antiemesis guidelines occurred in 34% and 24% of cisplatin and AC courses, respectively, because of omission of a NKl RA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients treated with HEC regimens experienced high avoidable acute care use, 1.8 times the risk seen for other chemotherapy. Nonadherence to guideline-directed antiemetic prophylaxis highlights the need to ensure adherence to antiemetic guidelines, including the use of NKl RA in HEC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>After survival, perhaps the most important goal in oncology is limiting avoidable acute care, a goal now used by Medicare to impact cancer reimbursement. This study found that patients treated with highly emetogenic chemotherapy (HEC) regimens had high rates of avoidable acute care use, 1.8 times the risk seen for other chemotherapy. A substantial proportion of the avoidable acute care involved chemotherapy-induced nausea and vomiting. Results showed that incomplete adherence to national antiemetic guidelines for HEC regimens primarily driven by omission of upfront neurokinin-1 receptor antagonist use, suggesting that improved adherence can meaningfully resolve this gap in quality and cost of care.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13620","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T08:36:25Z","timestamp":1606898185000},"page":"325-331","source":"Crossref","is-referenced-by-count":16,"title":["Avoidable Acute Care Use Associated with Nausea and Vomiting Among Patients Receiving Highly Emetogenic Chemotherapy or Oxaliplatin"],"prefix":"10.1093","volume":"26","author":[{"given":"Rudolph M.","family":"Navari","sequence":"first","affiliation":[{"name":"World Health Organization, Atlanta, Georgia, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Nipp","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Clark-Snow","sequence":"additional","affiliation":[{"name":"Oncology Supportive Care Consultant, Overland Park, Kansas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Schwartzberg","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Tennessee Health Sciences Center and West Cancer Center, Germantown, Tennessee, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Binder","sequence":"additional","affiliation":[{"name":"Helsinn Therapeutics (U.S.), Iselin, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Bailey","sequence":"additional","affiliation":[{"name":"Helsinn Therapeutics (U.S.), Iselin, New Jersey, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Potluri","sequence":"additional","affiliation":[{"name":"SmartAnalyst, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luke M.","family":"Schmerold","sequence":"additional","affiliation":[{"name":"SmartAnalyst, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eros","family":"Papademetriou","sequence":"additional","affiliation":[{"name":"SmartAnalyst, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric J.","family":"Roeland","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,21]]},"reference":[{"key":"2021122512175398700_onco13620-bib-0001","volume-title":"Total expenses and percent distribution for selected conditions by type of Service: United States, 2014. Medical Expenditure Panel Survey (MEPS) household component data","author":"Agency for Healthcare Research and Quality","year":"2014"},{"key":"2021122512175398700_onco13620-bib-0002","volume-title":"Cost drivers of cancer Care: A retrospective analysis of medicare and commercially insured claim data 2004-2014","author":"Fitch","year":"2016"},{"key":"2021122512175398700_onco13620-bib-0003","author":"Economic impact of cancer"},{"key":"2021122512175398700_onco13620-bib-0004","article-title":"Centers for Medicare & Medicaid Services. Medicare program: Section XIII, new hospital outpatient quality reporting program quality measures for the CY 2020 payment determinations and subsequent years \u2013 Final rule. US","volume":"81","author":"Department of Health and Human Services","year":"2016","journal-title":"Fed Regist"},{"key":"2021122512175398700_onco13620-bib-0005"},{"key":"2021122512175398700_onco13620-bib-0006"},{"key":"2021122512175398700_onco13620-bib-0007","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1080\/13696998.2019.1620244","article-title":"Budget impact of netupitant\/palonosetron for the prevention of chemotherapy-induced nausea and vomiting","volume":"22","author":"Park","year":"2019","journal-title":"J Med Econ"},{"key":"2021122512175398700_onco13620-bib-0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","article-title":"Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting","volume":"19","author":"Burke","year":"2011","journal-title":"Support Care Cancer."},{"key":"2021122512175398700_onco13620-bib-0009","first-page":"173","article-title":"Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system","volume":"8","author":"Rashid","year":"2016","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2021122512175398700_onco13620-bib-0010","author":"Healthcare resource utilization project","year":"2017"},{"key":"2021122512175398700_onco13620-bib-0011","volume-title":"NCCN Clinical Practice Guidelines in Oncology\u2013Antiemesis - Version 2.2020. Plymouth Meeting, PA: National Comprehensive Cancer Network","author":"National Comprehensive Cancer Network","year":"2020"},{"key":"2021122512175398700_onco13620-bib-0012","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: American Society of Clinical Oncology Clinical Practice guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"2021122512175398700_onco13620-bib-0013","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"2021122512175398700_onco13620-bib-0014","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): The Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122512175398700_onco13620-bib-0015","doi-asserted-by":"crossref","first-page":"294","DOI":"10.6004\/jnccn.2017.7043","article-title":"Ten year trends in antiemetic prescribing in cancer patients receiving highly emetogenic chemotherapy","volume":"16","author":"O'Sullivan","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122512175398700_onco13620-bib-0016","volume-title":"Gaps in compliance with current antiemetic guidelines for highly emetogenic chemotherapy. Poster presented at NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care. March 22\u201324","author":"Roeland"},{"key":"2021122512175398700_onco13620-bib-0017","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1200\/JOP.19.00457","article-title":"Impact of addition of carboplatin AUC \u22654 to antiemetic guidelines for triple antiemetic prophylaxis: A gap in quality of care, guideline adoption, and avoiding acute care","volume":"16","author":"Navari","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2021122512175398700_onco13620-bib-0018","article-title":"Admissions and Emergency Department Visits for Patients Receiving Outpatient Chemotherapy Measure Technical Report. Prepared by Mathematica Policy Research under subcontract to Yale New Haven Health Services Corporation","author":"Centers for Medicare and Medicaid Services","year":"2016","journal-title":"Center for Outcomes Research and Evaluation"},{"key":"2021122512175398700_onco13620-bib-0019","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122512175398700_onco13620-bib-0020","author":"Quality oncology practice initiative"},{"key":"2021122512175398700_onco13620-bib-0021","doi-asserted-by":"crossref","first-page":"676","DOI":"10.6004\/jnccn.2019.7526","article-title":"What the HEC? Clinician adherence to evidence-based antiemetic prophylaxis for highly emetogenic chemotherapy","volume":"18","author":"Roeland","year":"2020","journal-title":"J Natl Compr Canc Netork"},{"key":"2021122512175398700_onco13620-bib-0022","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1185\/03007995.2011.556603","article-title":"Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC\/MEC\/HEC)","volume":"27","author":"Schwartzberg","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"2021122512175398700_onco13620-bib-0023","volume-title":"NCCN Antiemesis Guidelines 3.2018. Plymouth Meeting, PA: National Comprehensive Cancer Network","author":"National Comprehensive Cancer Network","year":"2018"},{"key":"2021122512175398700_onco13620-bib-0024","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"key":"2021122512175398700_onco13620-bib-0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"2021122512175398700_onco13620-bib-0026","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"key":"2021122512175398700_onco13620-bib-0027","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1001\/jama.2018.18085","article-title":"Two-year survival comparing web-based symptom monitoring vs routine surveillance following treatment for lung cancer","volume":"321","author":"Denis","year":"2019","journal-title":"JAMA"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13620","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/4\/325\/41923336\/oncolo_26_4_325.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/4\/325\/41923336\/oncolo_26_4_325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T12:18:08Z","timestamp":1640434688000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/4\/325\/6445558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,21]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12,21]]},"published-print":{"date-parts":[[2021,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13620","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,12,21]]}}}